Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol.
about
Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse eventsRegular treatment with formoterol for chronic asthma: serious adverse eventsRegular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse eventsRegular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse eventsRegular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse eventsRegular treatment with formoterol for chronic asthma: serious adverse eventsRegular treatment with formoterol and inhaled steroids for chronic asthma: serious adverse eventsRegular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse eventsRegular treatment with salmeterol for chronic asthma: serious adverse eventsTolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial.What is new with the beta2-agonists: issues in the management of asthma.Beta-adrenergic receptor polymorphisms and drug responses in asthma.A long-acting β2-adrenergic agonist increases the expression of muscarine cholinergic subtype‑3 receptors by activating the β2-adrenoceptor cyclic adenosine monophosphate signaling pathway in airway smooth muscle cellsOvercoming beta-agonist tolerance: high dose salbutamol and ipratropium bromide. Two randomised controlled trialsAdvances in the management of pediatric asthma: a review of recent FDA drug approvals and label updates.Risk versus benefit considerations for the beta(2)-agonists.Non-corticosteroid therapy for the long-term control of asthma.Beta2-agonist tolerance and exercise-induced bronchospasm.Adverse effects of short-acting beta-agonists: potential impact when anti-inflammatory therapy is inadequate.What We Need To Know about Long-acting β2-AgonistsLoss of bronchoprotection to Salbutamol during sputum induction with hypertonic saline: implications for asthma therapy.
P2860
Q24199079-2C7DA31F-0FD0-4786-AD3A-B7D71B9933FFQ24200353-618DE5A0-8272-44AB-B180-AFEC221599FAQ24201048-61CDC5AD-18D1-410E-B2E1-65A3CBB12C15Q24202005-68B6CBF0-E57D-4754-BA3C-0D011F801B95Q24240282-D9A3D56C-81AA-484B-941E-14F1D0C0CC88Q24241250-A3E76B6B-76CA-4FF5-8C24-4925BB3A2914Q24241453-D67F7B01-C684-4023-B76C-3BDDC01D0552Q24241740-5F0D9295-778C-4BCB-8D48-6AF2BABACD04Q24241960-9D2344F9-794F-4138-AED3-73389AF6AEBBQ24816932-12BEEF25-2916-4383-9978-FD65E91D5F78Q33213762-220A92D5-AD24-43C2-881A-B88DA1FE3D3DQ34612106-E3A5942E-B236-423D-AFF0-6808F4B69AD2Q35388280-F7FAD458-B754-48AE-BA59-448CDD438FFEQ35677555-D82311E0-9DF0-4610-A0A6-BAD4DA2C5B6AQ36305143-7073E42A-B194-455D-A633-16AFE0DA3719Q36582709-C65C8BE8-27E9-46DA-974A-968014290718Q36916911-6201FA2B-0184-4BAE-A3CB-91D9880C3BF6Q43961067-F7CE1AF4-3B85-4883-A1D9-A3361072FEDBQ44925202-212FF214-7675-4FB2-9825-DD9B8193F207Q54981619-F3C57C8E-C02F-41D4-8744-250EE259C124Q55257587-6C495B85-3112-4125-AA81-78A0B4EF7A8F
P2860
Reversing acute bronchoconstriction in asthma: the effect of bronchodilator tolerance after treatment with formoterol.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Reversing acute bronchoconstri ...... ter treatment with formoterol.
@en
Reversing acute bronchoconstri ...... ter treatment with formoterol.
@nl
type
label
Reversing acute bronchoconstri ...... ter treatment with formoterol.
@en
Reversing acute bronchoconstri ...... ter treatment with formoterol.
@nl
prefLabel
Reversing acute bronchoconstri ...... ter treatment with formoterol.
@en
Reversing acute bronchoconstri ...... ter treatment with formoterol.
@nl
P2093
P1476
Reversing acute bronchoconstri ...... fter treatment with formoterol
@en
P2093
D R Taylor
E M Flannery
R J Hancox
P304
P356
10.1183/09031936.01.17303680
P577
2001-03-01T00:00:00Z